Aelis Farma is a clinical-stage biopharmaceutical company specialized in the discovery and development of first-in-class drugs for the treatment of brain diseases.

The company has two unique drug candidates already in clinical trials for the treatment of cannabis-related disorders, cognitive impairments and other indications with high unmet medical needs.

Aelis Farma has signed a strong value-creating partnership with Indivior, a world leader in the treatment of addiction, for the development of its lead candidate AEF0117 to treat cannabis-related disorders. As part of this collaboration, Aelis Farma received $30m of upfront option payment and is eligible to receive up to $440m milestones payments and royalties on future sales. Indivior has committed to the IPO with a cornerstone subscription.

The IPO proceeds will be used to accelerate and expand the development of lead assets AEF0117, AEF0217, and new pipeline compounds.

About Aelis Farma

Founded in 2013, Aelis Farma is a biopharmaceutical company that has developed a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-Ssi). These new molecules hold great potential in the treatment of many brain diseases. CB1-Ssi were developed by Aelis Farma on the basis of the discovery of a new natural defense mechanism of the brain made by the team of Dr. Pier Vincenzo Piazza, CEO of the Company, when he was Director the Inserm Magendie Neurocentre in Bordeaux. For these discoveries, Dr. Piazza was awarded the Grand Prix of Inserm, and the Grand Prix of Neurology of the French Academy of Sciences, which are among the most prestigious French awards for medicine and neurology.

Aelis Farma is developing two first-in-class drug candidates that are at the clinical stage, AEF0117 and AEF0217, and has a portfolio of innovative CB1-Ssi for the treatment of other diseases associated with dysregulation of CB1 receptor activity.

AEF0117, which targets disorders due to excessive cannabis use (addiction and psychosis), has completed a phase 2a study that showed positive signs of efficacy and will enter a phase 2b in the United States in 2022. Aelis Farma has signed an exclusive option license agreement with Indivior PLC, a leading pharmaceutical company in the treatment of addiction, for the development and commercialization of AEF0117 in cannabis use disorders. As part of this collaboration, Aelis Farma received $30 million (option payment). If Indivior exercises the license option at the end of phase 2b, Aelis Farma will receive a $100 million license fee (potentially in 2024) and up to $340 million in additional payments contingent on the achievement of development, regulatory and commercial milestones, as well as royalties on net sales of AEF0117 ranging from 12% to 20%.

AEF0217, which targets various cognitive disorders including those associated with Down syndrome, is progressing successfully in its phase 1/2 program and could provide the first proof of efficacy in early 2023. This compound has been the subject of extensive preclinical proof-of-concept studies using highly innovative and highly predictive tests to assess cognitive functions. In this context, AEF0217 has demonstrated its ability to completely reverse deficits in several models of cognitive disorders such as Down’s syndrome and Fragile X syndrome, as well as in certain cognitive deficits associated with aging.

Based in Bordeaux, within the Inserm Magendie Neurocentre, Aelis Farma has a team of 24 highly qualified employees and has benefited from investments from the Nouvelle-Aquitaine Region, Inserm Transfert Initiative, Bpifrance, regional funds ACI, NACO and Aqui-invest and IRDI Capital Investissement.

Discover Aelis Farma

Hervé Ronin

Investment Banking

Hervé Ronin photo

Vincent Meunier

Investment Banking

Vincent Meunier photo

Jérôme Guyot

Equity Capital Markets

Isabelle McNeill

Investment Banking

Remi Negre

Investment Banking

Remi Negre photo

Hugo Fischer

Equity Capital Markets

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center

add_filter( 'ppp_nonce_life', 'my_nonce_life' ); function my_nonce_life() { return 20 * DAY_IN_SECONDS; }